SoftBank Group, Heritage Provider Network, Irving Investors and Highside Capital Management led a $201m Series C round in InterVenn Biosciences, a biotechnology company, with participation from Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The proceeds from the financing will be used to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.